BioGaia AB (publ) (BGLAF)
- Previous Close
0.00 - Open
9.58 - Bid 10.32 x 41800
- Ask 11.04 x 38800
- Day's Range
9.58 - 9.58 - 52 Week Range
9.58 - 12.31 - Volume
1,200 - Avg. Volume
0 - Market Cap (intraday)
1.17B - Beta (5Y Monthly) 0.65
- PE Ratio (TTM)
30.90 - EPS (TTM)
0.31 - Earnings Date Jul 18, 2025
- Forward Dividend & Yield 0.18 (1.83%)
- Ex-Dividend Date May 8, 2025
- 1y Target Est
--
BioGaia AB (publ), a healthcare company, provides probiotic products worldwide. The company operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. The Adult Health segment provides gut health tablets, bone health tablets and oral health lozenges, as well as cultures, which are used as an ingredient in a licensee's dairy product. The Other segment provides packaging solutions. It sells its products through distribution partners or through its own distribution channels. BioGaia AB (publ) was founded in 1990 and is based in Stockholm, Sweden.
www.biogaia.com224
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: BGLAF
View MorePerformance Overview: BGLAF
Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BGLAF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BGLAF
View MoreValuation Measures
Market Cap
1.07B
Enterprise Value
936.42M
Trailing P/E
30.88
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.69
Price/Book (mrq)
6.05
Enterprise Value/Revenue
8.39
Enterprise Value/EBITDA
22.23
Financial Highlights
Profitability and Income Statement
Profit Margin
21.83%
Return on Assets (ttm)
11.48%
Return on Equity (ttm)
15.69%
Revenue (ttm)
1.42B
Net Income Avi to Common (ttm)
309.74M
Diluted EPS (ttm)
0.31
Balance Sheet and Cash Flow
Total Cash (mrq)
1.25B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
256.92M